Swiss Biotech Windward Bio Files for US IPO
The Basel-based company aims to list its shares on the Nasdaq to fund the development of new antibody treatments.
Updated on Oct. 23, 2026 in Biotech
Live Poll
Is now a good time for individual investors to put money into new biotech stocks?
Windward Bio has officially filed for a US initial public offering, planning to list its shares on the Nasdaq exchange under the ticker symbol WWB. The company, headquartered in Basel, Switzerland, focuses on creating antibody treatments for asthma, COPD, and inflammatory skin conditions.
Why it matters
The company intends to use the capital raised from this offering to advance the development of its pipeline, specifically the lead drug candidate WIN378. This candidate is designed to block thymic stromal lymphopoietin to address various chronic conditions.
The company has secured $365 million from investors including OrbiMed, Novo Holdings, Omega Funds, and Blue Owl Healthcare Opportunities. Novo Holdings currently holds a 14.5% pre-IPO stake, while Blue Owl Capital maintains a 5.9% stake.
The players
Windward Bio
A biotech firm based in Basel, Switzerland, that specializes in developing antibody treatments for inflammatory and respiratory conditions.
Novo Holdings
An investment firm that operates as a holding company and is the majority shareholder of Novo Nordisk.
Blue Owl Capital
An alternative asset management firm that provides direct lending and capital solutions to healthcare and technology companies.
The details
The drug development effort centers on WIN378, which functions by blocking thymic stromal lymphopoietin. Financial institutions Jefferies, TD Cowen, Piper Sandler, and UBS Investment Bank are serving as the underwriters for the upcoming offering.
Timeline
October 16, 2026: Windward Bio filed for a US initial public offering.
The Tech Race
The push to develop thymic stromal lymphopoietin-blocking antibodies represents a growing sector in immunology targeting specific inflammatory pathways. Windward Bio is positioning itself within this specialized biotech market alongside established pharmaceutical giants pursuing similar therapeutic targets.
Investors can monitor the upcoming Nasdaq listing to track the company's valuation and public market reception. For patients, the successful commercialization of these antibody treatments could eventually provide new therapeutic options for chronic asthma and skin conditions.
The takeaway
The move to list on the Nasdaq signals Windward Bio's transition from a private, investor-backed firm to a public entity. Investors and industry observers should watch for updates regarding the share price and the progress of the lead drug candidate, WIN378, in upcoming clinical phases.
Further reading
For more on the latest sector activity, visit the Biotech section.
Live Poll
Is now a good time for individual investors to put money into new biotech stocks?
